
APT Therapeutics Inc (AKA: Advanced Protein Technologies Inc.) Profile last edited on: 12/30/2019
CAGE: 4CDR9
UEI: KCGRRQA5CKR4
Business Identifier: Knowledge-based, computer-aided drug discovery engine: greatly accelerates drug development cycles Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
4041 Forest Park Avenue
Saint Louis, MO 63108
Saint Louis, MO 63108
(314) 800-4742 |
info@apt-therapeutics.com |
www.apt-therapeutics.com |
Location: Single
Congr. District: 01
County: St. Louis city
Congr. District: 01
County: St. Louis city
Public Profile
Initially dba sAdvanced Protein Technologies Inc., in 2002 the firm was renamed APT Therapeutics. The organizing principle of the firm has been the deelopment of powerful knowledge-based, computer-aided drug discovery engine to enable speed-up of drug development cycles. Genomics having become a primary driving force of the drug discovery process, APT's protein informatics technology can precisely identifying the correct therapeutic proteins and drug targets. As therapeutic protein candidates are identified, the properties of the proteins can be enhanced to increase the probability of clinical success. Then, APT's protein cheminformatics provides a powerful computational solution for developing and optimizing small molecule drug leads. APT Therapeutics is leveraging its platforms in protein informatics, protein cheminformatics, and protein engineering to develop optimized human apyrases as antiplatelet therapies for acute myocardial infarction, stroke, and transplantation complications. The business strategy is to out-license and/or co-develop the drug candidates with pharma partners. U
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
5-9Revenue Range
.5M-1MVC funded?
YesPublic/Private
Privately HeldStock Info
----IP Holdings
15-19Awards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2024 | 2 | NIH | $2,942,885 | |
Project Title: Multi-functional anti-thrombotic therapy for coronary microvascular obstruction | ||||
2023 | 2 | NIH | $2,719,541 | |
Project Title: Immunomodulatory Therapy for Neuropathic Pain | ||||
2021 | 1 | NIH | $259,576 | |
Project Title: Peripherally Acting Analgesic for Osteoarthritis Pain | ||||
2020 | 1 | NIH | $300,000 | |
Project Title: Anti-Inflammatory and Anti-Diabetic Therapy for Metabolic Syndrome | ||||
2019 | 2 | NIH | $1,902,274 | |
Project Title: Antithrombotic Therapy with No Bleeding Risk for Pci |
Key People / Management
Ridong Chen -- Founder and CEO
Brian L Clevinger -- Managing Director, Prolog Ventures
Eric Gulve -- President of BioGenerator
Soonseog Jeong -- Co-Founder
Eric Leire -- former President
Brian L Clevinger -- Managing Director, Prolog Ventures
Eric Gulve -- President of BioGenerator
Soonseog Jeong -- Co-Founder
Eric Leire -- former President